Issue of Equity

RNS Number : 7067S
Surgical Innovations Group PLC
11 November 2013
 



 

 

 

Surgical Innovations Group plc

("SI" or the "Company")

 

Issue of Equity

 

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical devices, announces that, following the exercise of options by a Director today, it has issued and allotted 140,000 ordinary shares of 1p each.

 

Details of the Director's options exercised and resulting shareholding is as follows:-

 


Number of options

Exercise price

Total shareholding following issue

Total shareholding percentage of enlarged issued share capital

Graham Bowland,

Chief Executive

140,000

1.5 pence

5,168,498

1.28%

 

Accordingly Application has been made to the London Stock Exchange for the 140,000 New Ordinary Shares of 1p each to be admitted to trading on AIM ("Admission"). It is expected that such Admission will occur on 19 November 2013. The new ordinary shares rank pari passu with the existing shares of the Company.

 

Following Admission the total number of ordinary shares in issue will be 404,731,902 with each share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the purposes of the Disclosure and Transparency Rules.

 

 

- ENDS -

 

Enquiries:

 

Surgical Innovations Group plc

Tel: +44 (0)113 230 7597

Graham Bowland, Chief Executive Officer

graham.bowland@surginno.co.uk

Mike Thornton, Chief Financial Officer

michael.thornton@surginno.co.uk

 

Panmure Gordon (Nominated Advisor & Broker)

www.panmure.com

Fred Walsh/ Freddy Crossley (Corporate Finance)

Tel: +44 (0)20 7886 2500

Adam Pollock (Corporate Broking)

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or si@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 



 

Notes to Editors:

 

About Surgical Innovations Group plc - www.sigroupplc.com 

 

Surgical Innovations Group plc specialises in the design and manufacture of creative solutions for minimally invasive surgery (MIS) and industrial markets. 

 

As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.

 

Over 100 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.

 

The Group's patented products are sold through three main channels:

 

SI brand

Through an established network of distribution partners, Surgical Innovations branded products are sold in major medical markets including North America, Britain, South East Asia, Australasia and the Indian subcontinent. 

 

OEM and IP

The Group supplies large medical device companies on an OEM basis, generating both sales and IP royalty fees.  Clients include Teleflex Medical, Olympus and CareFusion. 

 

Industrial

 

SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, in situ with minimum disassembly and downtime. 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOELFLFFXFFBFBE
UK 100

Latest directors dealings